Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN7 | P35236 | 5/20 | 0.48 |
| ▸ | HMGCR | P04035 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9015927 | 1.00 | PTPN7 (0.48) | PTPN7HMGCRTSHRTHRBRAB9A | |
| SCHEMBL1602080 | 1.00 | PTPN7 (0.48) | PTPN7HMGCRTSHRTHRBRAB9A | |
| SCHEMBL5166822 | 1.00 | PTPN7 (0.48) | PTPN7HMGCRTSHRTHRBRAB9A | |
| SCHEMBL9015838 | 1.00 | PTPN7 (0.48) | PTPN7HMGCRTSHRTHRBRAB9A | |
| SCHEMBL513133 | 1.00 | PTPN7 (0.48) | PTPN7HMGCRTSHRTHRBRAB9A | |
| SCHEMBL514166 | 1.00 | PTPN7 (0.48) | PTPN7HMGCRTSHRTHRBRAB9A | |
| SCHEMBL1174096 | 1.00 | PTPN7 (0.48) | PTPN7HMGCRTSHRTHRBRAB9A | |
| SCHEMBL54883 | 1.00 | — | — | |
| SCHEMBL512564 | 1.00 | PTPN7 (0.48) | PTPN7HMGCRTSHRTHRBRAB9A | |
| SCHEMBL6561950 | 1.00 | PTPN7 (0.48) | PTPN7HMGCRTSHRTHRBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4744089-A1 | SELECTIVE DEPOSITION OF ALUMINUM-CONTAINING DIELECTRIC MATERIAL ON DIELECTRIC OVER METAL UTILIZING ALKYNES | Versum Materials US, LLC (US) | 2026-05-20 | — | — | EP | claimed |
| US-20260130860-A1 | LIPIDS FOR DELIVERY OF THERAPEUTIC AGENTS | FLAGSHIP LABS 114, INC. (US) | 2026-05-14 | — | — | US | claimed |
| EP-4687854-A2 | LIPIDS AND LIPID-LIKE COMPOUNDS FOR THERAPEUTIC LIPID NANOPARTICLE (LNP) DELIVERY | Flagship Labs 114, Inc. (US) | 2026-02-11 | — | — | EP | claimed |
| WO-2025226985-A1 | PASSIVATION OF POLYSILICON MATERIAL AND SELECTIVE DEPOSITION OF DIELECTRIC MATERIAL UTILIZING ALKYNES | VERSUM MATERIALS US, LLC (US) | 2025-10-30 | — | — | WO | claimed |
| WO-2025038887-A1 | SELECTIVE DEPOSITION OF ALUMINUM-CONTAINING DIELECTRIC MATERIAL ON DIELECTRIC OVER METAL UTILIZING ALKYNES | VERSUM MATERIALS US, LLC (US) | 2025-02-20 | — | — | WO | claimed |
| WO-2024211865-A2 | LIPIDS AND LIPID-LIKE COMPOUNDS FOR THERAPEUTIC LIPID NANOPARTICLE (LNP) DELIVERY | OMEGA THERAPEUTICS, INC. (US) | 2024-10-10 | — | — | WO | claimed |
| WO-2024073678-A2 | PHOSPHOLIPIDS CONTAINING A HETEROCYCLE RING HAVING A TERTIARY AMINE OR AMIDE | OMEGA THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | claimed |
| WO-2023225621-A2 | LIPIDS FOR DELIVERY OF THERAPEUTIC AGENTS | OMEGA THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | WO | claimed |
| EP-1753708-B1 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS FOR MAKING THE SAME | UNIV BRIGHAM YOUNG (US) | 2018-02-21 | — | — | EP | claimed |
| EP-2142164-B1 | COSMETIC COMPOSITIONS COMPRISING ESTERS BASED ON 2-PROPYLHEPTANOIC ACID | COGNIS IP MAN GMBH (DE) | 2012-07-04 | — | — | EP | claimed |
| EP-2181763-B1 | Catalyst and process for alkoxylation | SHELL INT RESEARCH (NL) | 2012-06-20 | — | — | EP | claimed |
| EP-1052968-B1 | ALPHA-AMIDES OF(L)-AMINO ACIDS AS FRAGRANCE PRECURSORS | GILLETTE CO (US) | 2007-12-05 | — | — | EP | claimed |
| JP-5255128-A | — | — | None | — | — | JP | disclosed |
| EP-4744089-A1 | SELECTIVE DEPOSITION OF ALUMINUM-CONTAINING DIELECTRIC MATERIAL ON DIELECTRIC OVER METAL UTILIZING ALKYNES | Versum Materials US, LLC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20260130860-A1 | LIPIDS FOR DELIVERY OF THERAPEUTIC AGENTS | FLAGSHIP LABS 114, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4687854-A2 | LIPIDS AND LIPID-LIKE COMPOUNDS FOR THERAPEUTIC LIPID NANOPARTICLE (LNP) DELIVERY | Flagship Labs 114, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| JP-H05255128-A | PRODUCTION OF CIS-OLEFIN | SATOU FUMIE | 1993-10-05 | — | — | JP | disclosed |
| EP-0560532-A1 | Preparation of cis-olefins | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1993-09-15 | — | — | EP | disclosed |
| WO-1991004966-A1 | METHOD FOR PREPARING TECHNICAL MIXTURES OF SULPHATED 2-ALKYLIMIDAZOLINE DERIVATIVES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1991-04-18 | — | — | WO | disclosed |
| US-4988688-A | Cognitive activators | WARNER-LAMBERT COMPANY (US) | 1991-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260130860-A1 | LIPIDS FOR DELIVERY OF THERAPEUTIC AGENTS | NSUN3, NSUN2, LDLR | PTPN7 2194/4885HMGCR 460/4885TSHR 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.